{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T23:20:34Z","timestamp":1792106434486,"version":"4.4.0"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-65847-0","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T11:35:00Z","timestamp":1764675300000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Understanding interspecies drug response variations between human and rodent P2X7 receptors"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-2348-3591","authenticated-orcid":false,"given":"Chang-Run","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danqi","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Yuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian-Tian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Bao","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Ying","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Ping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1705-4905","authenticated-orcid":false,"given":"Jiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7684-2939","authenticated-orcid":false,"given":"Yu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2044-3074","authenticated-orcid":false,"given":"Peng","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5327-5337","authenticated-orcid":false,"given":"Motoyuki","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3685-6268","authenticated-orcid":false,"given":"Hong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4054-8543","authenticated-orcid":false,"given":"Ye","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,2]]},"reference":[{"key":"65847_CR1","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1124\/pr.113.008003","volume":"66","author":"R Bartlett","year":"2014","unstructured":"Bartlett, R., Stokes, L. & Sluyter, R. The P2X7 receptor channel: recent developments and the use of P2X7 antagonists in models of disease,. Pharmacol. Rev. 66, 638\u2013675 (2014).","journal-title":"Pharmacol. Rev."},{"key":"65847_CR2","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1111\/bph.15299","volume":"178","author":"P Illes","year":"2021","unstructured":"Illes, P. et al. Update of P2X receptor properties and their pharmacology: IUPHAR Review 30,. Br. J. Pharmacol. 178, 489\u2013514 (2021).","journal-title":"Br. J. Pharmacol."},{"key":"65847_CR3","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1146\/annurev-physiol-020518-114259","volume":"81","author":"R Schmid","year":"2019","unstructured":"Schmid, R. & Evans, R. J. ATP-Gated P2X Receptor channels: molecular insights into functional roles. Annu. Rev. Physiol. 81, 43\u201362 (2019).","journal-title":"Annu. Rev. Physiol."},{"key":"65847_CR4","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/S0140-6736(21)02348-5","volume":"399","author":"LP McGarvey","year":"2022","unstructured":"McGarvey, L. P. et al. Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials. Lancet 399, 909\u2013923 (2022).","journal-title":"Lancet"},{"key":"65847_CR5","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1007\/s40262-022-01126-1","volume":"61","author":"C Friedrich","year":"2022","unstructured":"Friedrich, C. et al. Safety, Pharmacodynamics, and Pharmacokinetics of P2X3 Receptor Antagonist Eliapixant (BAY 1817080) in Healthy Subjects: Double-Blind Randomized Study. Clin. Pharmacokinet. 61, 1143\u20131156 (2022).","journal-title":"Clin. Pharmacokinet."},{"key":"65847_CR6","first-page":"A5778","volume":"205","author":"JA Smith","year":"2022","unstructured":"Smith, J. A. et al. Safety and Efficacy of BLU-5937 In the Treatment of Refractory Chronic Cough from the Phase 2b Soothe Trial. Am. J. Respir. Crit. Care Med. 205, A5778 (2022).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"65847_CR7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00408-022-00592-5","volume":"201","author":"L McGarvey","year":"2023","unstructured":"McGarvey, L. et al. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 2b Trial of P2X3 Receptor Antagonist Sivopixant for Refractory or Unexplained Chronic Cough. Lung 201, 25\u201335 (2023).","journal-title":"Lung"},{"key":"65847_CR8","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s11302-020-09743-w","volume":"17","author":"K Inoue","year":"2021","unstructured":"Inoue, K. Nociceptive signaling of P2X receptors in chronic pain states. Purinergic Signal 17, 41\u201347 (2021).","journal-title":"Purinergic Signal"},{"key":"65847_CR9","doi-asserted-by":"publisher","first-page":"291","DOI":"10.3389\/fphar.2017.00291","volume":"8","author":"L Stokes","year":"2017","unstructured":"Stokes, L. et al. P2X4 Receptor Function in the Nervous System and Current Breakthroughs in Pharmacology. Front. Pharmacol. 8, 291\u2013305 (2017).","journal-title":"Front. Pharmacol."},{"key":"65847_CR10","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/j.1365-2125.2012.04320.x","volume":"75","author":"Z Ali","year":"2013","unstructured":"Ali, Z. et al. Pharmacokinetic and pharmacodynamic profiling of a P2X7 receptor allosteric modulator GSK1482160 in healthy human subjects. Br. J. Clin. Pharmacol. 75, 197\u2013207 (2013).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"65847_CR11","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1177\/0269881120914206","volume":"34","author":"K Recourt","year":"2020","unstructured":"Recourt, K. et al. Characterisation of the pharmacodynamic effects of the P2X7 receptor antagonist JNJ-54175446 using an oral dexamphetamine challenge model in healthy males in a randomised, double-blind, placebo-controlled, multiple ascending dose trial. J. Psychopharmacol. 34, 1030\u20131042 (2020).","journal-title":"J. Psychopharmacol."},{"key":"65847_CR12","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1038\/s41386-018-0141-6","volume":"43","author":"A Bhattacharya","year":"2018","unstructured":"Bhattacharya, A. et al. Neuropsychopharmacology of JNJ-55308942: evaluation of a clinical candidate targeting P2X7 ion channels in animal models of neuroinflammation and anhedonia. Neuropsychopharmacology 43, 2586\u20132596 (2018).","journal-title":"Neuropsychopharmacology"},{"key":"65847_CR13","unstructured":"ClinicalTrials. Study of SGM-1019 in Patients with Nonalcoholic Steatohepatitis (NASH) https:\/\/clinicaltrials.gov\/study\/NCT03676231?term=SGM-1019&rank=1."},{"key":"65847_CR14","doi-asserted-by":"publisher","first-page":"720","DOI":"10.3899\/jrheum.110874","volume":"39","author":"TC Stock","year":"2012","unstructured":"Stock, T. C. et al. Efficacy and safety of CE-224,535, an antagonist of P2X7 receptor, in treatment of patients with rheumatoid arthritis inadequately controlled by methotrexate. J. Rheumatol. 39, 720\u2013727 (2012).","journal-title":"J. Rheumatol."},{"key":"65847_CR15","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1136\/annrheumdis-2011-143578","volume":"71","author":"EC Keystone","year":"2012","unstructured":"Keystone, E. C. et al. Clinical evaluation of the efficacy of the P2X7 purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine. Ann. Rheum. Dis. 71, 1630\u20131635 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"65847_CR16","unstructured":"Asahi-Kasei. Lilly and Asahi Kasei Pharma Announce License Agreement for Chronic Pain Drug Candidatehttps:\/\/www.asahi-kasei.com\/news\/2020\/e210129_2.html"},{"key":"65847_CR17","doi-asserted-by":"crossref","unstructured":"Iqbal. J. et al. A patent review of P2X7 receptor antagonists to treat inflammatory diseases (2018 - present), Expert Opin. Ther. Patents, 2024.","DOI":"10.1080\/13543776.2024.2363885"},{"key":"65847_CR18","doi-asserted-by":"crossref","unstructured":"Tang H., et al. P2X7 receptors: a bibliometric review from 2002 to 2023, Purinergic Signal, 2024.","DOI":"10.1007\/s11302-024-09996-9"},{"key":"65847_CR19","doi-asserted-by":"publisher","first-page":"108228","DOI":"10.1016\/j.pharmthera.2022.108228","volume":"237","author":"E Genetzakis","year":"2022","unstructured":"Genetzakis, E. et al. Development and clinical translation of P2X7 receptor antagonists: A potential therapeutic target in coronary artery disease?. Pharmacol. Ther. 237, 108228\u2013108248 (2022).","journal-title":"Pharmacol. Ther."},{"key":"65847_CR20","doi-asserted-by":"publisher","first-page":"1033135","DOI":"10.3389\/fphar.2022.1033135","volume":"13","author":"W Sch\u00e4fer","year":"2022","unstructured":"Sch\u00e4fer, W. et al. Origin, distribution, and function of three frequent coding polymorphisms in the gene for the human P2X7 ion channel. Front. Pharmacol. 13, 1033135\u20131033147 (2022).","journal-title":"Front. Pharmacol."},{"key":"65847_CR21","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/bs.apcsb.2015.11.004","volume":"104","author":"E De Marchi","year":"2016","unstructured":"De Marchi, E. et al. P2X7 receptor as a therapeutic target. Adv. Protein Chem. Struct. Biol. 104, 39\u201379 (2016).","journal-title":"Adv. Protein Chem. Struct. Biol."},{"key":"65847_CR22","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1007\/s00259-019-04369-6","volume":"46","author":"D Van Weehaeghe","year":"2019","unstructured":"Van Weehaeghe, D. et al. 11C]JNJ54173717, a novel P2X7 receptor radioligand as marker for neuroinflammation: human biodistribution, dosimetry, brain kinetic modelling and quantification of brain P2X7 receptors in patients with Parkinson\u2019s disease and healthy volunteers. Eur. J. Nucl. Med. Mol. Imaging 46, 2051\u20132064 (2019).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"65847_CR23","unstructured":"Nicke, A. The P2X7 Receptor Methods and Protocols. Humana Press."},{"key":"65847_CR24","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.4155\/fmc-2017-0044","volume":"9","author":"E Cichero","year":"2017","unstructured":"Cichero, E. & Tonelli, M. Targeting species-specific trace amine-associated receptor 1 ligands: to date perspective of the rational drug design process. Future Med. Chem. 9, 1507\u20131527 (2017).","journal-title":"Future Med. Chem."},{"key":"65847_CR25","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1002\/prot.26302","volume":"90","author":"D Sheng","year":"2022","unstructured":"Sheng, D. & Hattori, M. Recent progress in the structural biology of P2X receptors. Proteins 90, 1779\u20131785 (2022).","journal-title":"Proteins"},{"key":"65847_CR26","doi-asserted-by":"publisher","first-page":"5844","DOI":"10.1038\/s41467-023-41495-0","volume":"14","author":"C Guo","year":"2023","unstructured":"Guo, C. et al. Chronic cough relief by allosteric modulation of P2X3 without taste disturbance. Nat. Commun. 14, 5844\u20135862 (2023).","journal-title":"Nat. Commun."},{"key":"65847_CR27","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.pupt.2019.03.007","volume":"56","author":"G Denis","year":"2019","unstructured":"Denis, G. & Nathalie, C. BLU-5937: A selective P2X3 antagonist with potent anti-tussive effect and no taste alteration. Pulm. Pharmacol. Ther. Vol. 56, 56\u201362 (2019).","journal-title":"Pulm. Pharmacol. Ther. Vol."},{"key":"65847_CR28","doi-asserted-by":"publisher","first-page":"6437","DOI":"10.1038\/s41467-023-42164-y","volume":"14","author":"C Shen","year":"2023","unstructured":"Shen, C. et al. Structural insights into the allosteric inhibition of P2X4 receptors. Nat. Commun. 14, 6437\u20136452 (2023).","journal-title":"Nat. Commun."},{"key":"65847_CR29","doi-asserted-by":"publisher","first-page":"e22153","DOI":"10.7554\/eLife.22153","volume":"5","author":"A Karasawa","year":"2016","unstructured":"Karasawa, A. & Kawate, T. Structural basis for subtype-specific inhibition of the P2X7 receptor. ELife 5, e22153 (2016).","journal-title":"ELife"},{"key":"65847_CR30","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1111\/bph.16273","volume":"181","author":"DP Wang","year":"2024","unstructured":"Wang, D. P. et al. Druggable site near the upper vestibule determines the high affinity and P2X3 homotrimer selectivity of sivopixant\/S-600918 and its analogue DDTPA. Br. J. Pharmacol. 181, 1203\u20131220 (2024).","journal-title":"Br. J. Pharmacol."},{"key":"65847_CR31","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1124\/jpet.106.111559","volume":"319","author":"P Honore","year":"2006","unstructured":"Honore, P. et al. A-740003 [N-(1-{[(cyanoimino)(5-quinolinylamino) methyl]amino}-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide], a novel and selective P2X7 receptor antagonist, dose-dependently reduces neuropathic pain in the rat. J. Pharmacol. Exp. Ther. 319, 1376\u20131385 (2006).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"65847_CR32","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1111\/j.1476-5381.2009.00233.x","volume":"157","author":"DL Donnelly-Roberts","year":"2009","unstructured":"Donnelly-Roberts, D. L. et al. Mammalian P2X7 receptor pharmacology: comparison of recombinant mouse, rat and human P2X7 receptors. Br. J. Pharmacol. 157, 1203\u20131214 (2009).","journal-title":"Br. J. Pharmacol."},{"key":"65847_CR33","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1124\/mol.114.096222","volume":"87","author":"AR Ase","year":"2015","unstructured":"Ase, A. R. et al. Identification and Characterization of a Selective Allosteric Antagonist of Human P2X4 Receptor Channels. Mol. Pharmacol. 87, 606\u2013616 (2015).","journal-title":"Mol. Pharmacol."},{"key":"65847_CR34","doi-asserted-by":"publisher","first-page":"8225","DOI":"10.3390\/ijms24098225","volume":"24","author":"R Sluyter","year":"2023","unstructured":"Sluyter, R. et al. Animal Models for the Investigation of P2X7 Receptors. Int. J. Mol. Sci. 24, 8225\u20138255 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"65847_CR35","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/j.bmcl.2008.11.088","volume":"19","author":"L Ga","year":"2009","unstructured":"Ga, L. et al. Synthesis and structure\u2013activity relationships of novel, substituted 5,6-dihydrodibenzo [a,g] quinolizinium P2X7 antagonists. Bioorg. Med. Chem. Lett. 19, 954\u2013958 (2009).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"65847_CR36","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1111\/bph.12314","volume":"170","author":"A Bhattacharya","year":"2013","unstructured":"Bhattacharya, A. et al. Pharmacological characterization of a novel centrally permeable P2X7 receptor antagonist: JNJ-47965567. Br. J. Pharmacol. 170, 624\u2013640 (2013).","journal-title":"Br. J. Pharmacol."},{"key":"65847_CR37","doi-asserted-by":"publisher","first-page":"108109","DOI":"10.1016\/j.jbc.2024.108109","volume":"301","author":"T Thach","year":"2015","unstructured":"Thach, T. et al. Mechanistic insights into the selective targeting of P2X3 receptor by camlipixant antagonist. J. Biol. Chem. 301, 108109 (2015).","journal-title":"J. Biol. Chem."},{"key":"65847_CR38","doi-asserted-by":"publisher","first-page":"4559","DOI":"10.1021\/acs.jmedchem.7b00408","volume":"60","author":"MA Letavic","year":"2017","unstructured":"Letavic, M. A. et al. 4-Methyl-6,7-dihydro-4H -triazolo [4,5-c] pyridine-Based P2X7 Receptor Antagonists: Optimization of Pharmacokinetic Properties Leading to the Identification of a Clinical Candidate. J. Med. Chem. 60, 4559\u20134572 (2017).","journal-title":"J. Med. Chem."},{"key":"65847_CR39","doi-asserted-by":"publisher","first-page":"RP92829","DOI":"10.7554\/eLife.92829","volume":"12","author":"D Sheng","year":"2024","unstructured":"Sheng, D. et al. Structural insights into the orthosteric inhibition of P2X receptors by non-ATP analog antagonists. ELife 12, RP92829 (2024).","journal-title":"ELife"},{"key":"65847_CR40","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.cell.2019.09.017","volume":"179","author":"AE McCarthy","year":"2019","unstructured":"McCarthy, A. E., Yoshioka, C. & Mansoor, S. E. Full-Length P2X7 Structures Reveal How Palmitoylation Prevents Channel Desensitization. Cell 179, 659\u2013670 (2019).","journal-title":"Cell"},{"key":"65847_CR41","doi-asserted-by":"publisher","first-page":"E3786","DOI":"10.1073\/pnas.1701379114","volume":"114","author":"M Harkat","year":"2017","unstructured":"Harkat, M. et al. On the permeation of large organic cations through the pore of ATP-gated P2X receptors. Proc. Natl. Acad. Sci. USA 114, E3786\u2013E3795 (2017).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"65847_CR42","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1515\/BC.2007.061","volume":"388","author":"O Boehm","year":"2007","unstructured":"Boehm, O. et al. Clinical chemistry reference database for Wistar rats and C57\/BL6 mice. Biol. Chem. 388, 547\u2013554 (2007).","journal-title":"Biol. Chem."},{"key":"65847_CR43","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/s41568-018-0037-0","volume":"18","author":"F Di Virgilio","year":"2018","unstructured":"Di Virgilio, F. et al. Extracellular ATP and P2 purinergic signalling in the tumour microenvironment. Nat. Rev. Cancer 18, 601\u2013618 (2018).","journal-title":"Nat. Rev. Cancer"},{"key":"65847_CR44","doi-asserted-by":"publisher","first-page":"S60","DOI":"10.1016\/S0168-8278(18)30341-6","volume":"68","author":"K Dabbagh","year":"2018","unstructured":"Dabbagh, K. et al. Preclinical and first-in human development of SGM-1019, a first-in-class novel small molecule modulator of inflammasome activity for the treatment of nonalcoholic steatohepatitis (NASH). J. Hepatol. 68, S60 (2018).","journal-title":"J. Hepatol."},{"key":"65847_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.celrep.2019.03.011","volume":"27","author":"S Zumerle","year":"2019","unstructured":"Zumerle, S. et al. Intercellular Calcium Signaling Induced by ATP Potentiates Macrophage Phagocytosis. Cell Rep. 27, 1\u201310 (2019).","journal-title":"Cell Rep."},{"key":"65847_CR46","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1089\/wound.2019.1103","volume":"10","author":"S Li","year":"2021","unstructured":"Li, S. et al. Diagnostics for wound infections. Adv. Wound Care 10, 317\u2013327 (2021).","journal-title":"Adv. Wound Care"},{"key":"65847_CR47","doi-asserted-by":"publisher","first-page":"10772","DOI":"10.1021\/acsnano.8b01152","volume":"12","author":"Y Xi","year":"2018","unstructured":"Xi, Y. et al. Biomimetic elastomeric polypeptide-based nanofibrous matrix for overcoming multidrug-resistant bacteria and enhancing full-thickness wound healing\/skin regeneration. ACS Nano 12, 10772\u201310784 (2018).","journal-title":"ACS Nano"},{"key":"65847_CR48","first-page":"n771","volume":"9","author":"H Zhang","year":"2023","unstructured":"Zhang, H. et al. Switching from membrane disrupting to membrane crossing, an effective strategy in designing antibacterial polypeptide. Sci. Adv. 9, n771 (2023).","journal-title":"Sci. Adv."},{"key":"65847_CR49","doi-asserted-by":"publisher","first-page":"6405","DOI":"10.1021\/acs.jmedchem.8b01749","volume":"62","author":"S Lu","year":"2019","unstructured":"Lu, S. et al. Allosteric modulator discovery: from serendipity to structure-based design. J. Med. Chem. 62, 6405\u20136421 (2019).","journal-title":"J. Med. Chem."},{"key":"65847_CR50","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/sj.bjp.0707625","volume":"153","author":"AD Michel","year":"2008","unstructured":"Michel, A. D., Chambers, L. J. & Walter, D. S. Negative and positive allosteric modulators of the P2X(7) receptor. Br. J. Pharmacol. 153, 737\u2013750 (2008).","journal-title":"Br. J. Pharmacol."},{"key":"65847_CR51","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1124\/pr.110.002667","volume":"62","author":"NJ Smith","year":"2010","unstructured":"Smith, N. J. & Milligan, G. Allostery at G protein-coupled receptor homo- and heteromers: uncharted pharmacological landscapes. Pharmacol. Rev. 62, 701\u2013725 (2010).","journal-title":"Pharmacol. Rev."},{"key":"65847_CR52","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.pupt.2019.03.007","volume":"56","author":"D Garceau","year":"2019","unstructured":"Garceau, D. & Chauret, N. BLU-5937: A selective P2X3 antagonist with potent anti-tussive effect and no taste alteration. Pulm. Pharmacol. Ther. 56, 56\u201362 (2019).","journal-title":"Pulm. Pharmacol. Ther."},{"key":"65847_CR53","doi-asserted-by":"publisher","first-page":"1101023","DOI":"10.3389\/fphar.2023.1101023","volume":"14","author":"G Pasqualetto","year":"2023","unstructured":"Pasqualetto, G. et al. Identification of the molecular determinants of antagonist potency in the allosteric binding pocket of human P2X4. Front. Pharmacol. 14, 1101023\u20131101132 (2023).","journal-title":"Front. Pharmacol."},{"key":"65847_CR54","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3389\/fncel.2019.00121","volume":"13","author":"AR Ase","year":"2019","unstructured":"Ase, A. R., Therrien, E. & Seguela, P. An allosteric inhibitory site conserved in the Ectodomain of P2X receptor channels. Front. Cell. Neurosci. 13, 121\u2013131 (2019).","journal-title":"Front. Cell. Neurosci."},{"key":"65847_CR55","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1111\/j.1476-5381.2009.00135.x","volume":"156","author":"D Michel","year":"2009","unstructured":"Michel, D. et al. Mechanism of action of species-selective P2X7 receptor antagonists. Br. J. Pharmacol. 156, 1312\u20131325 (2009).","journal-title":"Br. J. Pharmacol."},{"key":"65847_CR56","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.tcb.2018.01.005","volume":"28","author":"F Di Virgilio","year":"2018","unstructured":"Di Virgilio, F., Schmalzing, G. & Markwardt, F. The Elusive P2X7 Macropore. Trends Cell Biol. 28, 392\u2013404 (2018).","journal-title":"Trends Cell Biol."},{"key":"65847_CR57","doi-asserted-by":"publisher","first-page":"793","DOI":"10.3389\/fphar.2020.00793","volume":"11","author":"R Lara","year":"2020","unstructured":"Lara, R. et al. P2X7 in cancer: from molecular mechanisms to therapeutics. Front. Pharmacol. 11, 793\u2013822 (2020).","journal-title":"Front. Pharmacol."},{"key":"65847_CR58","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s11302-021-09783-w","volume":"17","author":"AC Sarti","year":"2021","unstructured":"Sarti, A. C., Vultaggio-Poma, V. & Di Virgilio, F. P2X7: a receptor with a split personality that raises new hopes for anti-cancer therapy. Purinergic Signal 17, 175\u2013178 (2021).","journal-title":"Purinergic Signal"},{"key":"65847_CR59","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1038\/nm.2028","volume":"15","author":"F Ghiringhelli","year":"2009","unstructured":"Ghiringhelli, F. et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat. Med. 15, 1170\u20131178 (2009).","journal-title":"Nat. Med."},{"key":"65847_CR60","doi-asserted-by":"publisher","first-page":"4939","DOI":"10.1073\/pnas.1800907115","volume":"115","author":"J Wang","year":"2018","unstructured":"Wang, J. et al. Druggable negative allosteric site of P2X3 receptors. Proc. Natl. Acad. Sci. USA 115, 4939\u20134944 (2018).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"65847_CR61","doi-asserted-by":"publisher","first-page":"102002","DOI":"10.1016\/j.jbc.2022.102002","volume":"298","author":"X Ma","year":"2022","unstructured":"Ma, X. et al. The long \u03b22,3-sheets encoded by redundant sequences play an integral role in the channel function of P2X7 receptors. J. Biol. Chem. 298, 102002\u2013102014 (2022).","journal-title":"J. Biol. Chem."},{"key":"65847_CR62","doi-asserted-by":"publisher","first-page":"107396","DOI":"10.1016\/j.jsb.2019.09.013","volume":"208","author":"C Wu","year":"2019","unstructured":"Wu, C. et al. High-quality, high-throughput cryo-electron microscopy data collection via beam tilt and astigmatism-free beam-image shift. J. Struct. Biol. 208, 107396\u2013107401 (2019).","journal-title":"J. Struct. Biol."},{"key":"65847_CR63","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/nmeth.4193","volume":"14","author":"SQ Zheng","year":"2017","unstructured":"Zheng, S. Q. et al. MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy. Nat. Methods 14, 331\u2013332 (2017).","journal-title":"Nat. Methods"},{"key":"65847_CR64","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.jsb.2015.08.008","volume":"192","author":"A Rohou","year":"2015","unstructured":"Rohou, A. & Grigorieff, N. CTFFIND4: Fast and accurate defocus estimation from electron micrographs. J. Struct. Biol. 192, 216\u2013221 (2015).","journal-title":"J. Struct. Biol."},{"key":"65847_CR65","doi-asserted-by":"publisher","first-page":"e42166","DOI":"10.7554\/eLife.42166","volume":"7","author":"J Zivanov","year":"2018","unstructured":"Zivanov, J. et al. New tools for automated high-resolution cryo-EM structure determination in RELION-3. ELife 7, e42166 (2018).","journal-title":"ELife"},{"key":"65847_CR66","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1038\/s41592-020-00990-8","volume":"17","author":"A Punjani","year":"2020","unstructured":"Punjani, A., Zhang, H. & Fleet, D. J. Non-uniform refinement: adaptive regularization improves single-particle cryo-EM reconstruction. Nat. Methods 17, 1214\u20131221 (2020).","journal-title":"Nat. Methods"},{"key":"65847_CR67","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1107\/S0907444910007493","volume":"66","author":"P Emsley","year":"2010","unstructured":"Emsley, P. et al. Features and development of Coot. Acta Crystallogr. Sect. D. -Biol. Crystallogr. 66, 486\u2013501 (2010).","journal-title":"Acta Crystallogr. Sect. D. -Biol. Crystallogr."},{"key":"65847_CR68","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1107\/S2059798319011471","volume":"75","author":"D Liebschner","year":"2019","unstructured":"Liebschner, D. et al. Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix. Acta Crystallogr. Sect. D. -Struct. Biol. 75, 861\u2013877 (2019).","journal-title":"Acta Crystallogr. Sect. D. -Struct. Biol."},{"key":"65847_CR69","unstructured":"Schr\u00f6dinger L. Schr\u00f6dinger Release 2018-1 Desmond. 2018."},{"key":"65847_CR70","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1016\/j.csbj.2022.03.030","volume":"20","author":"W Cui","year":"2022","unstructured":"Cui, W. et al. P2X3-selective mechanism of Gefapixant, a drug candidate for the treatment of refractory chronic cough. Comput. Struct. Biotechnol. J. 20, 1642\u20131653 (2022).","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"65847_CR71","doi-asserted-by":"publisher","first-page":"11225","DOI":"10.1021\/ja9621760","volume":"118","author":"WL Jorgensen","year":"1996","unstructured":"Jorgensen, W. L. et al. Development and testing of the OPL Sall-atom force field on conformational energetics and properties of organic liquids. J. Am. Chem. Soc. 118, 11225\u201311236 (1996).","journal-title":"J. Am. Chem. Soc."},{"key":"65847_CR72","doi-asserted-by":"publisher","first-page":"11225","DOI":"10.1021\/ja9621760","volume":"118","author":"WL Jorgensen","year":"1996","unstructured":"Jorgensen, W. L. & Maxwell, D. S. TiradoRives J. Development and testingoftheOPLSall-atomforcefield on conformational energetics and properties of organic liquids. J. Am. Chem. Soc. 118, 11225\u201311236 (1996). 12.","journal-title":"J. Am. Chem. Soc."},{"key":"65847_CR73","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1002\/jcc.20292","volume":"26","author":"JL Banks","year":"2005","unstructured":"Banks, J. L. et al. Integrated Modeling Program, Applied Chemical Theory (IMPACT). J. Comput. Chem. 26, 1752\u20131780 (2005).","journal-title":"J. Comput. Chem."},{"key":"65847_CR74","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/j.scib.2022.02.016","volume":"67","author":"M Sun","year":"2022","unstructured":"Sun, M. et al. Vanilloid agonist-mediated activation of TRPV1 channels requires coordinated movement of the S1\u2013S4 bundle rather than a quiescent state. Sci. Bull. 67, 1062\u20131076 (2022).","journal-title":"Sci. Bull."},{"key":"65847_CR75","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-33167-7","volume":"8","author":"FR Stahl","year":"2018","unstructured":"Stahl, F. R. et al. Laboratory diagnostics of murine blood for detection of mouse cytomegalovirus (MCMV)-induced hepatitis. Sci. Rep. 8, 14823 (2018).","journal-title":"Sci. Rep."},{"key":"65847_CR76","doi-asserted-by":"publisher","first-page":"173168","DOI":"10.1016\/j.pbb.2021.173168","volume":"204","author":"P Knight","year":"2021","unstructured":"Knight, P. et al. Sex differences in the elevated plus-maze test and large open field test in adult Wistar rats. Pharmacol. Biochem. Behav. 204, 173168 (2021).","journal-title":"Pharmacol. Biochem. Behav."},{"key":"65847_CR77","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-12986-9","volume":"12","author":"H Ueno","year":"2022","unstructured":"Ueno, H. et al. Effect of simultaneous testing of two mice in the tail suspension test and forced swim test. Sci. Rep. 12, 9224 (2022).","journal-title":"Sci. Rep."},{"key":"65847_CR78","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/sj.bjp.0704851","volume":"137","author":"T Yamamoto","year":"2002","unstructured":"Yamamoto, T., Nozaki-Taguchi, N. & Chiba, T. Analgesic effect of intrathecally administered orexin-A in the rat formalin test and in the rat hot plate test. Br. J. Pharmacol. 137, 170\u2013176 (2002).","journal-title":"Br. J. Pharmacol."},{"key":"65847_CR79","doi-asserted-by":"publisher","first-page":"114417","DOI":"10.1016\/j.bbr.2023.114417","volume":"446","author":"AD Modi","year":"2023","unstructured":"Modi, A. D., Parekh, A. & Pancholi, Y. N. Evaluating pain behaviours: Widely used mechanical and thermal methods in rodents. Behav. Brain Res. 446, 114417 (2023).","journal-title":"Behav. Brain Res."},{"key":"65847_CR80","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1038\/s41596-018-0116-4","volume":"14","author":"Z Fan","year":"2019","unstructured":"Fan, Z. et al. Using the tube test to measure social hierarchy in mice. Nat. Protoc. 14, 819\u2013831 (2019).","journal-title":"Nat. Protoc."},{"key":"65847_CR81","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S0165-0270(96)02211-X","volume":"73","author":"K Matsuura","year":"1997","unstructured":"Matsuura, K. et al. Pole test is a useful method for evaluating the mouse movement disorder caused by striatal dopamine depletion. J. Neurosci. Methods 73, 45\u201348 (1997).","journal-title":"J. Neurosci. Methods"},{"key":"65847_CR82","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/S0924-8579(02)00110-3","volume":"20","author":"D Ordway","year":"2002","unstructured":"Ordway, D. et al. Intracellular activity of clinical concentrations of phenothiazines including thioridiazine against phagocytosed Staphylococcus aureus. Int. J. Antimicrob. Agents 20, 34\u201343 (2002).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"65847_CR83","doi-asserted-by":"publisher","first-page":"e01637-21","DOI":"10.1128\/spectrum.01637-21","volume":"9","author":"L Benov","year":"2021","unstructured":"Benov, L. Improved formazan dissolution for bacterial MTT assay. Microbiol. Spectr. 9, e01637-21 (2021).","journal-title":"Microbiol. Spectr."},{"key":"65847_CR84","doi-asserted-by":"crossref","unstructured":"Laskowski, R. A. & Swindells, M. B. LigPlot+: multiple ligand-protein interaction diagrams for drug discovery. J. Chem. Inf. Model. 51, 2778\u20132786 (2011).","DOI":"10.1021\/ci200227u"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-65847-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-65847-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-65847-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T13:02:30Z","timestamp":1764680550000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-65847-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,2]]},"references-count":84,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["65847"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-65847-0","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,2]]},"assertion":[{"value":"29 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10827"}}